Array BioPharma to Present at the 22nd Annual Piper Jaffray Health Care Conference

BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the 22nd Annual Piper Jaffray Health Care Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Event:

  22nd Annual Piper Jaffray Health Care Conference

Presenter:

Robert E. Conway, Chief Executive Officer, Array BioPharma

Date:

Tuesday, November 30, 2010

Time:

3:00 p.m. Eastern Time

Location:

The New York Palace, NYC

Webcast:

www.arraybiopharma.com

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to www.arraybiopharma.com.



CONTACT:

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.